Oncology Drug Reference Sheet: Eflornithine
Chelsea Backler MSN, APRN, AGCNS-BC, AOCNS®, VA-BC
Voice
Description
Eflornithine (Iwilfin™) is the first U.S. Food and Drug Administration–approved oral maintenance therapy for high-risk neuroblastoma. Approved in December 2023, eflornithine has an orphan drug designation.